Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS candidate RFK Jr told senators the GLP-1s are ‘miracle drugs’ but shouldn’t ...

Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

More and more Americans are turning to GLP-1 injections to lose weight. FOX 7 Austin's Rebecca Thomas spoke to an Austin physician to discuss.

Medications that have transformed the treatment of obesity may also help people drink less alcohol, according to new government-funded research.

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

Exclusive: ASA calls number of parallel probes ‘significant’ and describes tackling issue as ‘priority’ after it issued ...

Glucagon-like peptide-1 receptor agonist medications for weight loss are significantly transforming the field of facial plastic surgery.